全文获取类型
收费全文 | 382813篇 |
免费 | 28157篇 |
国内免费 | 13660篇 |
专业分类
耳鼻咽喉 | 4908篇 |
儿科学 | 12184篇 |
妇产科学 | 4723篇 |
基础医学 | 46391篇 |
口腔科学 | 9401篇 |
临床医学 | 38904篇 |
内科学 | 62062篇 |
皮肤病学 | 7662篇 |
神经病学 | 19688篇 |
特种医学 | 15823篇 |
外国民族医学 | 147篇 |
外科学 | 46606篇 |
综合类 | 44918篇 |
现状与发展 | 71篇 |
预防医学 | 18583篇 |
眼科学 | 7930篇 |
药学 | 35274篇 |
105篇 | |
中国医学 | 9340篇 |
肿瘤学 | 39910篇 |
出版年
2023年 | 4259篇 |
2022年 | 6510篇 |
2021年 | 14375篇 |
2020年 | 10694篇 |
2019年 | 16150篇 |
2018年 | 11215篇 |
2017年 | 10735篇 |
2016年 | 12830篇 |
2015年 | 16469篇 |
2014年 | 27232篇 |
2013年 | 26218篇 |
2012年 | 27847篇 |
2011年 | 25688篇 |
2010年 | 22766篇 |
2009年 | 22134篇 |
2008年 | 21365篇 |
2007年 | 21571篇 |
2006年 | 18868篇 |
2005年 | 14614篇 |
2004年 | 10282篇 |
2003年 | 8976篇 |
2002年 | 7335篇 |
2001年 | 6208篇 |
2000年 | 5258篇 |
1999年 | 4134篇 |
1998年 | 3970篇 |
1997年 | 3758篇 |
1996年 | 3283篇 |
1995年 | 3412篇 |
1994年 | 3126篇 |
1993年 | 2493篇 |
1992年 | 2450篇 |
1991年 | 2273篇 |
1990年 | 2017篇 |
1989年 | 1927篇 |
1988年 | 1776篇 |
1987年 | 1491篇 |
1986年 | 1299篇 |
1985年 | 2398篇 |
1984年 | 2411篇 |
1983年 | 1733篇 |
1982年 | 1851篇 |
1981年 | 1734篇 |
1980年 | 1489篇 |
1979年 | 1257篇 |
1978年 | 944篇 |
1977年 | 893篇 |
1976年 | 767篇 |
1974年 | 481篇 |
1973年 | 468篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
52.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
53.
《European journal of surgical oncology》2022,48(6):1264-1271
BackgroundIn order to avoid excessive treatment of thyroid nodules in the clinic, it is necessary to find a simple and practical analysis method to comprehensively and accurately reflect benign or malignant thyroid nodules. This study aimed to construct and validate a comprehensive and reliable network-based predictive model using a variety of imaging and laboratory criteria for thyroid nodules to stratify the risk of malignancy prior to surgery.MethodsWe retrospectively analyzed data from patients who underwent surgical treatment for thyroid nodules at the Thyroid and Breast Diagnosis and Treatment Center of Weifang Hospital of Traditional Chinese Medicine between January 2018 and December 2020. Binary logical regression analysis was performed to predict whether nodules were malignant or benign. The developmental dataset included 457 patients (January 2018–December 2020). The validation set included separate data points (n = 225, January 2018–December 2020).ResultsIn this study, criteria that showed significant predictive value for malignant nodules included TI-RADS: 4b (p = 0.065); Bethesda IV, Bethesda V, Bethesda VI (P < 0.0001); BRAFV600E mutation (P < 0.0001); Calcitonin>5 pg/ml (p = 0.0037); and FNA-Tg>30 ng/ml (p = 0.0003). A 10-grade risk scoring system was developed. The risk of malignancy risk ranged from 2.06% to 100% and was positively associated with increasing risk grade. The areas under the receiver-operating characteristic curve of the development and validation sets were 0.972 and 0.946, respectively.ConclusionA simple, comprehensive and reliable web-based predictive model was designed using a variety of imaging and laboratory criteria to stratify thyroid nodules by probability of malignancy. 相似文献
54.
55.
56.
- DNA is the sequence that codes for proteins.
- Messenger RNA is transcribed from the DNA sequence of genes and translated into protein.
- It can be difficult to predict how a change in the DNA sequence will affect messenger RNA and protein quantity and quality.
- DNA translocation changes can cause the joining of sequences from two different genes or different parts of the same gene.
- DNA sequencing is often used clinically to predict how DNA changes might affect proteins.
- Alternatively, RNA sequencing can be used as a more direct measure of the effect of DNA changes on the protein products.
- This sequencing is important for identifying changes in cancer that may indicate response to targeted therapy, prognosis, or diagnosis.
57.
《Drug discovery today》2022,27(6):1733-1742
Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action. 相似文献
58.
59.
《Journal of vascular and interventional radiology : JVIR》2022,33(6):631-638
PurposeTo test the following hypotheses: (a) balloon or stent assistance increases coil packing density (CPD) in the endovascular treatment of intracranial aneurysms, and (b) CPD correlates to ostium area (OA) and aneurysm volume (AV).Materials and MethodsThis retrospective study included 60 aneurysms (54 ruptured and 6 unruptured) treated with simple coiling (SC) (n = 18), balloon-assisted coiling (BAC) (n = 7), or stent-assisted coiling (SAC) (n = 35) at the authors’ institution between August 2017 and December 2019. AV and OA measurements were obtained from 3-dimensional digital subtraction angiography images using commercial software. Coil sizes were retrieved from patient files, and coil volume (CV) measurements were obtained from https://www.angiocalc.com/. Analysis of covariance, multivariate covariance analysis, and Pearson correlation analyses were performed.ResultsThe median value for AV, CV, CPD, and OA was 63.4 mm3 (range, 5.5–1,771.4 mm3), 23.13 mm3 (range, 2.03–296.95 mm3), 33.29% (range, 13.41%–81.02%), and 10.7 mm2 (range, 2.7–49.9 mm2), respectively. Multivariate analysis showed that the CPD values were not significantly different among the treatment groups, although OA significantly differed between the SC and SAC groups (P < .05). Pearson correlations showed that similar to AV, OA was negatively correlated with CPD (r = ?0.321, P < .05).ConclusionsThe CPD value in cerebral aneurysms treated with BAC or SAC did not differ from that in aneurysms treated with SC. 相似文献
60.